DK2459216T3 - Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer - Google Patents
Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorerInfo
- Publication number
- DK2459216T3 DK2459216T3 DK10766332.0T DK10766332T DK2459216T3 DK 2459216 T3 DK2459216 T3 DK 2459216T3 DK 10766332 T DK10766332 T DK 10766332T DK 2459216 T3 DK2459216 T3 DK 2459216T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunogenic compositions
- compositions including
- compounds
- activity modulators
- tlr activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23915609P | 2009-09-02 | 2009-09-02 | |
| PCT/IB2010/002386 WO2011027222A2 (en) | 2009-09-02 | 2010-09-01 | Immunogenic compositions including tlr activity modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2459216T3 true DK2459216T3 (da) | 2013-12-09 |
Family
ID=43415378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10766332.0T DK2459216T3 (da) | 2009-09-02 | 2010-09-01 | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9950062B2 (da) |
| EP (1) | EP2459216B1 (da) |
| JP (1) | JP5988492B2 (da) |
| CN (1) | CN102844047B (da) |
| AU (1) | AU2010290896B2 (da) |
| BR (1) | BR112012004806B8 (da) |
| CA (1) | CA2772916C (da) |
| CL (1) | CL2012000585A1 (da) |
| DK (1) | DK2459216T3 (da) |
| EA (1) | EA026401B1 (da) |
| ES (1) | ES2443952T3 (da) |
| MX (1) | MX2012002723A (da) |
| NZ (1) | NZ598654A (da) |
| SG (1) | SG178954A1 (da) |
| WO (1) | WO2011027222A2 (da) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012004806B8 (pt) | 2009-09-02 | 2022-10-04 | Novartis Ag | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso |
| RS54489B1 (en) | 2010-07-06 | 2016-06-30 | Glaxosmithkline Biologicals Sa | LIPOSOMS WITH LIPIDS THAT HAVE IMPROVED PKA VALUE FOR RNA RELEASE |
| JP5940064B2 (ja) | 2010-07-06 | 2016-06-29 | ノバルティス アーゲー | 低用量のｒｎａを用いた大型哺乳動物の免疫化 |
| LT3243526T (lt) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Rnr pristatymas, skirtas keleto imuninio atsako paleidimui |
| PL2611461T3 (pl) | 2010-08-31 | 2022-07-04 | Glaxosmithkline Biologicals Sa | Pegylowane liposomy do dostarczania rna kodującego immunogen |
| US9315530B2 (en) * | 2010-09-01 | 2016-04-19 | Novartis Ag | Adsorption of immunopotentiators to insoluble metal salts |
| EP4098324A1 (en) | 2010-10-11 | 2022-12-07 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| EP2652511B8 (en) | 2010-12-14 | 2017-06-28 | GlaxoSmithKline Biologicals SA | Flow cytometry analysis of materials adsorbed to metal salts |
| BR112013017283A2 (pt) | 2011-01-10 | 2016-10-25 | Cleveland Biolabs Inc | uso de agonista de receptor do tipo toll para tratamento de câncer |
| CA2828844C (en) | 2011-03-02 | 2020-07-14 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| EP2502631A1 (en) * | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
| JP2014517279A (ja) | 2011-05-10 | 2014-07-17 | ネステク ソシエテ アノニム | 個別治療管理のための疾患活動性プロファイリングの方法 |
| BR112013032675A2 (pt) * | 2011-06-19 | 2017-08-08 | Vaxine Pty Ltd | composição adjuvante de vacina compreendendo partículas de inulina |
| ES2656050T3 (es) * | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Composiciones de combinación inmunogénica y usos de las mismas |
| JP2014525429A (ja) | 2011-09-01 | 2014-09-29 | ノバルティス アーゲー | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 |
| EP2793939A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Stable compositions for immunising against staphylococcus aureus |
| WO2013131984A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
| JP2015510872A (ja) * | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| LT2822947T (lt) | 2012-03-07 | 2016-10-10 | Glaxosmithkline Biologicals Sa | Tlr7 agonisto arginino druskos |
| CA2866406A1 (en) * | 2012-03-08 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| IN2014KN02929A (da) | 2012-07-06 | 2015-05-08 | Novartis Ag | |
| US10000545B2 (en) | 2012-07-27 | 2018-06-19 | Institut National De La Sante Et De La Recherche Medicale | CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia |
| CN103566369B (zh) * | 2012-08-01 | 2015-11-25 | 中国医学科学院肿瘤医院 | 一种在慢性乙肝病毒感染状态下诱导机体产生特异性免疫的乙肝疫苗 |
| US20150203543A1 (en) | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
| DK2890394T3 (da) | 2012-08-31 | 2019-07-15 | Glaxosmithkline Biologicals Sa | Stabiliserede proteiner til immunisering mod Staphylococcus aureus |
| CN104602705A (zh) | 2012-09-06 | 2015-05-06 | 诺华股份有限公司 | 血清组b脑膜炎球菌和d/t/p的联合疫苗 |
| JP2016506416A (ja) * | 2013-01-10 | 2016-03-03 | ノバルティス アーゲー | インフルエンザウイルス免疫原性組成物およびその使用 |
| CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
| EP3798229A1 (en) | 2014-03-25 | 2021-03-31 | Yale University | Uses of parasite macrophage migration inhibitory factors |
| SI3122378T1 (sl) | 2014-03-26 | 2020-03-31 | Glaxosmithkline Biologicals S.A. | Mutantni stafilokokni antigeni |
| WO2016019034A1 (en) | 2014-07-30 | 2016-02-04 | Cleveland Biolabs, Inc. | Flagellin compositons and uses |
| CA2963218C (en) | 2014-10-03 | 2023-10-24 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| EP3206708B1 (en) | 2014-10-16 | 2022-11-02 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| US10420836B2 (en) | 2015-10-08 | 2019-09-24 | Emory University | Methods of immunizing a subject and compositions related thereto |
| AU2016349693B2 (en) | 2015-11-06 | 2022-08-11 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
| CN109310773B (zh) * | 2016-05-16 | 2022-04-26 | 传染病研究所 | 含有tlr激动剂的配制品和使用方法 |
| WO2018087699A2 (en) * | 2016-11-09 | 2018-05-17 | The Board Of Regents Of The University Of Texas System | Methods and compositions for adaptive immune modulation |
| US11464854B2 (en) * | 2017-03-23 | 2022-10-11 | Children's Medical Center Corporation | Methods and compositions relating to adjuvants |
| CN107167524A (zh) * | 2017-03-27 | 2017-09-15 | 万全万特制药（厦门）有限公司 | 气相色谱法分离检测阿立哌唑有关物质的方法 |
| MX2019012525A (es) | 2017-04-19 | 2019-12-05 | Glaxosmithkline Biologicals Sa | Proteinas de citomegalovirus modificadas y complejos estabilizados. |
| AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| KR20200009095A (ko) | 2017-05-31 | 2020-01-29 | 프로메테우스 바이오사이언시즈, 인크. | 크론병 환자에서 점막 치유를 평가하는 방법 |
| WO2019079160A1 (en) | 2017-10-16 | 2019-04-25 | Adjuvance Technologies, Inc. | TRITERPENIC SAPONIN ANALOGS |
| CN108218982A (zh) * | 2018-02-02 | 2018-06-29 | 暨南大学 | 人巨细胞病毒anti-UL148多克隆抗体及其制备方法与应用 |
| KR20200138234A (ko) | 2018-02-28 | 2020-12-09 | 유니버시티 오브 워싱톤 | 자기 조립 나노구조 백신 |
| US10730901B2 (en) | 2018-07-27 | 2020-08-04 | Aperta Biosciences, Llc | Spinosyn formulations for treatment of demodex-induced ocular and facial conditions |
| CN109191326B (zh) * | 2018-08-23 | 2021-11-30 | 东北大学 | 基于攻击方视角的配电网cps相依存系统网络攻击风险评估方法 |
| CA3116175A1 (en) | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| CN113227125A (zh) | 2018-12-12 | 2021-08-06 | 葛兰素史密丝克莱恩生物有限公司 | 用于o-连接的糖基化的修饰的载体蛋白 |
| US20220096526A1 (en) * | 2019-01-22 | 2022-03-31 | Tufts Medical Center, Inc. | Methods and compositions for the treatment and prevention of ocular diseases and conditions |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CN111892648B (zh) * | 2020-06-08 | 2022-08-26 | 中国科学院上海药物研究所 | 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用 |
| WO2022011014A1 (en) * | 2020-07-09 | 2022-01-13 | Exocure Biosciences, Inc. | Bacteria-derived vesicles and use thereof for generating immune response to sars-cov-2 |
| WO2022103967A1 (en) | 2020-11-13 | 2022-05-19 | Icosavax, Inc. | Protein-based nanoparticle vaccine for metapneumovirus |
| CN114053410A (zh) * | 2021-11-24 | 2022-02-18 | 肖军宏 | 一种治疗冠状病毒感染及其相关症状的大蒜素制剂 |
| CN114539426B (zh) * | 2022-03-02 | 2023-07-07 | 山东仙普爱瑞科技股份有限公司 | 一种含干扰素α的融合蛋白、表达该融合蛋白的重组菌株及其制备方法 |
| KR20250025527A (ko) | 2022-05-17 | 2025-02-21 | 아이코사백스, 인크. | 파라믹소바이러스용 다가 백신 및 이의 용도 |
| GB202215414D0 (en) | 2022-10-18 | 2022-11-30 | Glaxosmithkline Biologicals Sa | Vaccine |
| CN117003898B (zh) * | 2023-09-27 | 2023-12-29 | 贝格探索(成都)科技有限公司 | 一种lhrh4-crm197-lf多聚重组蛋白及其制备方法和应用 |
Family Cites Families (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE67769T1 (de) | 1983-01-25 | 1991-10-15 | Ciba Geigy Ag | Neue peptidderivate. |
| US5059258A (en) | 1989-08-23 | 1991-10-22 | Aluminum Company Of America | Phosphonic/phosphinic acid bonded to aluminum hydroxide layer |
| US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| JP3368902B2 (ja) | 1992-03-02 | 2003-01-20 | カイロン エセ．ピー．アー． | ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質 |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| CA2194236C (en) | 1994-07-01 | 2009-02-24 | Dermot Kelleher | Helicobacter proteins and vaccines |
| ATE235471T1 (de) | 1994-11-24 | 2003-04-15 | Basilea Pharmaceutica Ag | Neue benzylpyrimidine |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
| EP0909323B1 (en) | 1996-01-04 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Helicobacter pylori bacterioferritin |
| EP0907738A1 (en) | 1996-04-02 | 1999-04-14 | Smithkline Beecham Corporation | Novel compounds |
| EP0914330A4 (en) | 1996-05-14 | 2002-01-09 | Smithkline Beecham Corp | NEW TYPE COMPOUNDS |
| WO1998018931A2 (en) | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
| GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| PT991761E (pt) | 1997-08-21 | 2008-04-28 | Staat Nl Verteg Door Min Welzi | Mutantes novos de bactérias gram negativas das mucosas e a sua aplicação em vacinas. |
| DE69841807D1 (de) | 1997-11-06 | 2010-09-16 | Novartis Vaccines & Diagnostic | Neisseriale antigene |
| WO1999027109A2 (en) | 1997-11-26 | 1999-06-03 | Inhibitex, Inc. | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS) |
| EP2210945B1 (en) | 1998-01-14 | 2013-06-26 | Novartis Vaccines and Diagnostics S.r.l. | Neisseria meningitidis antigens |
| CA2328399A1 (en) | 1998-04-23 | 1999-10-28 | University Of Alabama At Birmingham | Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor |
| DK1645631T3 (da) | 1998-05-01 | 2008-02-18 | Novartis Vaccines & Diagnostic | Neisseria antigener og præparater |
| GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
| JP2002521058A (ja) | 1998-07-27 | 2002-07-16 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌由来の核酸及びタンパク質 |
| WO2000006737A2 (en) | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | Streptococcus pneumoniae proteins and nucleic acid molecules |
| CA2341018C (en) | 1998-08-31 | 2012-07-31 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Polypeptides and polynucleotides from coagulase-negative staphylococci |
| WO2000012131A1 (en) | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| MXPA01003557A (es) | 1998-10-09 | 2004-04-05 | Chiron Corp | Secuencias genomicas de neisseria y metodos para su uso. |
| GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| DK1140157T3 (da) | 1998-12-21 | 2009-06-08 | Medimmune Inc | Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner |
| CN1198932C (zh) | 1999-03-26 | 2005-04-27 | 科特克斯(Om)有限公司 | 肺炎链球菌抗原 |
| CA2371714C (en) | 1999-06-10 | 2012-12-04 | Medimmune, Inc. | Streptococcus pneumoniae proteins and vaccines |
| GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
| WO2001034642A2 (en) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Control of neisserial membrane synthesis |
| MXPA02006962A (es) | 2000-01-17 | 2002-12-13 | Chiron Spa | Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b. |
| ES2386534T3 (es) | 2000-02-28 | 2012-08-22 | Novartis Vaccines And Diagnostics S.R.L. | Expresión heteróloga de proteínas de Neisseria |
| DE10012370A1 (de) | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
| JP4852211B2 (ja) | 2000-03-21 | 2012-01-11 | メルク アンド カンパニー インコーポレイテッド | 原核生物における必須遺伝子の同定 |
| EP1278856A2 (en) | 2000-04-27 | 2003-01-29 | Medimmune, Inc. | Immunogenic pneumococcal protein and vaccine compositions thereof |
| NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
| US6495079B1 (en) | 2000-06-28 | 2002-12-17 | Prisma Fibers, Inc. | Process to prepare polymeric fibers with improved color and appearance |
| GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| US20040005667A1 (en) | 2000-07-03 | 2004-01-08 | Giuloi Ratti | Immunisation against chlamydia pneumoniae |
| US20040091495A1 (en) | 2000-07-20 | 2004-05-13 | Lars Bjorck | Protein |
| CA2416137C (en) | 2000-07-27 | 2013-01-29 | Dan Granoff | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| WO2002034773A2 (en) | 2000-10-26 | 2002-05-02 | Imperial College Innovations Ltd. | Streptococcal genes |
| AU1412702A (en) | 2000-10-27 | 2002-05-06 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a and b |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| AU2002306849A1 (en) | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
| ATE557041T1 (de) | 2001-05-18 | 2012-05-15 | Us Gov Health & Human Serv | Peptid-vakzinen gegen streptokokken der gruppe a |
| WO2002102829A2 (en) | 2001-06-15 | 2002-12-27 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| CA2453937C (en) | 2001-08-02 | 2013-05-14 | University Of Sheffield | Antigenic polypeptides |
| CA2469620A1 (en) | 2001-12-12 | 2003-06-19 | Chiron Srl. | Immunisation against chlamydia trachomatis |
| GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
| EP2275121B1 (en) | 2002-04-02 | 2013-06-12 | Ben Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
| GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| ATE359295T1 (de) | 2002-06-11 | 2007-05-15 | Glaxosmithkline Biolog Sa | Immunogene zusammensetzungen |
| JP2005533057A (ja) | 2002-06-13 | 2005-11-04 | ニューヨーク・ユニバーシティ | 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用 |
| GB0213622D0 (en) | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
| MXPA05000842A (es) | 2002-08-02 | 2005-04-28 | Glaxosmithkline Biolog Sa | Composicion de vacuna que comprende proteina de enlace de transferrina y hsf de bacteria gram-negativa. |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| US20070036828A1 (en) | 2002-09-13 | 2007-02-15 | Chiron Corporation | Group b streptococcus vaccine |
| AU2003274511B2 (en) | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| US7818252B2 (en) | 2003-02-20 | 2010-10-19 | Gilat Satellite Networks, Ltd | Enforcement of network service level agreements |
| AU2004230485B2 (en) | 2003-04-10 | 2009-01-22 | Novartis Vaccines And Diagnostics, Inc. | The severe acute respiratory syndrome coronavirus |
| EP2333114A1 (en) | 2003-04-15 | 2011-06-15 | Intercell AG | S. pneumoniae antigens |
| SI1644389T1 (sl) | 2003-06-16 | 2011-06-30 | Acad Of Science Czech Republic | Pirimidinske spojine s fosfonatnimi skupinami kot antivirusni nukleotidni analogi |
| JP4896715B2 (ja) | 2003-06-26 | 2012-03-14 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物 |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| ES2505695T3 (es) | 2003-07-31 | 2014-10-10 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunógenas para Streptococcus pyogenes |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| CA2555342A1 (en) * | 2004-02-18 | 2005-09-01 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| CA2557353A1 (en) | 2004-03-02 | 2005-09-15 | Chiron Corporation | Immunogenic compositions for chlamydia pneunomiae |
| GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| JP2007531768A (ja) | 2004-03-31 | 2007-11-08 | ニューヨーク・ユニバーシティ | 感染症、癌および自己免疫疾患を治療するための新規な合成ｃ−糖脂質、その合成および使用 |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| US20080085289A1 (en) | 2004-09-22 | 2008-04-10 | Cindy Castado | Immunogenic Composition |
| EP1855715B1 (en) | 2005-01-27 | 2013-03-13 | Children's Hospital & Research Center at Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| NZ597685A (en) | 2005-02-18 | 2013-12-20 | Novartis Vaccines & Diagnostic | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| CN101180312A (zh) | 2005-02-18 | 2008-05-14 | 诺华疫苗和诊断公司 | 来自尿路病原性大肠杆菌的免疫原 |
| WO2006137953A1 (en) | 2005-04-01 | 2006-12-28 | The Regents Of The Univerisity Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
| WO2006138004A2 (en) | 2005-05-12 | 2006-12-28 | Novartis Vaccines And Diagnostics, Inc. | Immunogenic compositions for chlamydia trachomatis |
| PT1896061T (pt) | 2005-06-27 | 2019-08-01 | Glaxosmithkline Biologicals Sa | Composição imunogénica |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2007034917A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
| JPWO2007034916A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| US20090118263A1 (en) | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
| US20090192153A1 (en) | 2005-09-22 | 2009-07-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| EP1976557A2 (en) | 2005-12-22 | 2008-10-08 | Novartis Vaccines and Diagnostics S.r.l. | Chlamydial antigens |
| CA2635269A1 (en) | 2005-12-27 | 2007-10-25 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
| CA2637598A1 (en) | 2006-01-18 | 2007-02-14 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| JP2009528989A (ja) | 2006-02-17 | 2009-08-13 | ファイザー・リミテッド | Ｔｌｒ７変調剤としての３−デアザプリン誘導体 |
| JP2009538116A (ja) | 2006-02-17 | 2009-11-05 | ノバルティス アーゲー | 細菌抗原の精製 |
| ES2376492T3 (es) * | 2006-03-23 | 2012-03-14 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores. |
| ES2388556T3 (es) | 2006-03-23 | 2012-10-16 | Novartis Ag | Compuestos inmunopotenciadores |
| AR060188A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
| US20100021503A1 (en) | 2006-03-30 | 2010-01-28 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
| US8338593B2 (en) | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| GB0616306D0 (en) | 2006-08-16 | 2006-09-27 | Novartis Ag | Vaccines |
| EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
| ATE511398T1 (de) | 2006-09-07 | 2011-06-15 | Glaxosmithkline Biolog Sa | Inaktiviertes poliovirus mischimpfstoff |
| WO2008047174A1 (en) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
| CL2008000496A1 (es) | 2007-02-19 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de purina; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades infecciosas, cancer, alergias y otras afecciones inflamatorias. |
| PE20081887A1 (es) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
| JP5400763B2 (ja) | 2007-05-08 | 2014-01-29 | アストラゼネカ・アクチエボラーグ | 免疫調節特性を有するイミダゾキノリン類 |
| WO2009019553A2 (en) | 2007-08-03 | 2009-02-12 | Pfizer Limited | Imidazopyridinones |
| ES2383231T3 (es) | 2007-10-19 | 2012-06-19 | Novartis Ag | Formulaciones para vacunas meningocócicas |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| CN101971030A (zh) | 2007-12-24 | 2011-02-09 | 诺华有限公司 | 流感吸附疫苗的试验 |
| HUE027249T2 (en) * | 2008-03-03 | 2016-10-28 | Novartis Ag | TLR activity modulator compounds and preparations |
| CN103396415B (zh) | 2008-03-24 | 2016-08-10 | 4Sc股份有限公司 | 新的取代的咪唑并喹啉化合物 |
| EP2303236A4 (en) | 2008-07-01 | 2012-09-26 | Univ Emory | SYNERGISTIC INDUCTION OF HUMOR AND CELLULAR IMMUNITY BY COMBINATORY ACTIVATION OF TOLL-LIKE RECEPTORS |
| US8242106B2 (en) | 2008-08-01 | 2012-08-14 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| TWM352127U (en) | 2008-08-29 | 2009-03-01 | Bestac Advanced Material Co Ltd | Polishing pad |
| AP2011005745A0 (en) | 2008-12-09 | 2011-06-30 | Gilead Sciences Inc | Modulators of toll-like receptors. |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| PE20110992A1 (es) | 2009-02-17 | 2012-02-12 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende un antigeno del virus del dengue |
| EP2419129A2 (en) | 2009-04-14 | 2012-02-22 | Novartis AG | Compositions for immunising against staphylococcus aerus |
| KR20120035168A (ko) | 2009-06-01 | 2012-04-13 | 노파르티스 아게 | 폐렴구균 ＲｒｇＢ 클레이드의 조합 |
| EP2440245B1 (en) * | 2009-06-10 | 2017-12-06 | GlaxoSmithKline Biologicals SA | Benzonaphthyridine-containing vaccines |
| US20110076300A1 (en) | 2009-08-27 | 2011-03-31 | Mariagrazia Pizza | Hybrid Polypeptides Including Meningococcal fHBP Sequences |
| BR112012004806B8 (pt) | 2009-09-02 | 2022-10-04 | Novartis Ag | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| EP2498815A4 (en) | 2009-11-09 | 2014-03-19 | Nat Jewish Health | VACCINE COMPOSITION |
| EA031379B1 (ru) | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| CA2796314A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
| US9315530B2 (en) | 2010-09-01 | 2016-04-19 | Novartis Ag | Adsorption of immunopotentiators to insoluble metal salts |
| EP2652511B8 (en) | 2010-12-14 | 2017-06-28 | GlaxoSmithKline Biologicals SA | Flow cytometry analysis of materials adsorbed to metal salts |
| CA2828844C (en) | 2011-03-02 | 2020-07-14 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| JP2014525429A (ja) | 2011-09-01 | 2014-09-29 | ノバルティス アーゲー | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 |
| LT2822947T (lt) | 2012-03-07 | 2016-10-10 | Glaxosmithkline Biologicals Sa | Tlr7 agonisto arginino druskos |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| WO2013131984A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
| CA2866406A1 (en) * | 2012-03-08 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| CN104602705A (zh) | 2012-09-06 | 2015-05-06 | 诺华股份有限公司 | 血清组b脑膜炎球菌和d/t/p的联合疫苗 |
| US20150258190A1 (en) | 2012-10-25 | 2015-09-17 | Novartis Ag | Nicotinamide as adjuvant |
-
2010
- 2010-09-01 BR BR112012004806A patent/BR112012004806B8/pt active IP Right Grant
- 2010-09-01 WO PCT/IB2010/002386 patent/WO2011027222A2/en active Application Filing
- 2010-09-01 CA CA2772916A patent/CA2772916C/en active Active
- 2010-09-01 CN CN201080049574.8A patent/CN102844047B/zh active Active
- 2010-09-01 EA EA201270356A patent/EA026401B1/ru not_active IP Right Cessation
- 2010-09-01 US US13/394,036 patent/US9950062B2/en active Active
- 2010-09-01 AU AU2010290896A patent/AU2010290896B2/en not_active Ceased
- 2010-09-01 EP EP10766332.0A patent/EP2459216B1/en active Active
- 2010-09-01 NZ NZ598654A patent/NZ598654A/en not_active IP Right Cessation
- 2010-09-01 ES ES10766332.0T patent/ES2443952T3/es active Active
- 2010-09-01 SG SG2012014833A patent/SG178954A1/en unknown
- 2010-09-01 JP JP2012527403A patent/JP5988492B2/ja active Active
- 2010-09-01 MX MX2012002723A patent/MX2012002723A/es active IP Right Grant
- 2010-09-01 DK DK10766332.0T patent/DK2459216T3/da active
-
2012
- 2012-03-02 CL CL2012000585A patent/CL2012000585A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120237546A1 (en) | 2012-09-20 |
| CA2772916A1 (en) | 2011-03-10 |
| WO2011027222A2 (en) | 2011-03-10 |
| BR112012004806B8 (pt) | 2022-10-04 |
| AU2010290896A1 (en) | 2012-04-05 |
| EP2459216A2 (en) | 2012-06-06 |
| CL2012000585A1 (es) | 2012-09-14 |
| EA026401B1 (ru) | 2017-04-28 |
| ES2443952T3 (es) | 2014-02-21 |
| BR112012004806A2 (pt) | 2016-11-29 |
| JP2013503845A (ja) | 2013-02-04 |
| AU2010290896B2 (en) | 2014-07-03 |
| JP5988492B2 (ja) | 2016-09-07 |
| US9950062B2 (en) | 2018-04-24 |
| EA201270356A1 (ru) | 2012-09-28 |
| CN102844047A (zh) | 2012-12-26 |
| CA2772916C (en) | 2019-01-15 |
| BR112012004806B1 (pt) | 2020-12-29 |
| MX2012002723A (es) | 2012-04-11 |
| SG178954A1 (en) | 2012-04-27 |
| WO2011027222A3 (en) | 2011-05-05 |
| EP2459216B1 (en) | 2013-10-30 |
| NZ598654A (en) | 2014-05-30 |
| CN102844047B (zh) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2459216T3 (da) | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer | |
| MX2012002654A (es) | Compuestos y composiciones como moduladores de la actividad de tlr. | |
| JO3065B1 (ar) | مركبات وتركيبات كمعدلات لفاعلية tlr | |
| MX341395B (es) | Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc. | |
| MX347471B (es) | Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas. | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| GT201200258A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BR112013001613A2 (pt) | compostos tricíclicos e métodos para fazer e usar os mesmos. | |
| MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
| MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
| AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| MX392150B (es) | Moduladores de receptores canabinoides. | |
| UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
| BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| BR112015010196A2 (pt) | métodos de tratar doença do fígado | |
| EA201290319A1 (ru) | Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания |